FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 上海昊海生物科技股份有限公司（於中華人民共和國註冊成立的股份有限公司） 呈交日期： 2024年10月30日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | | 普通股 | 股份類別 | H | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | | 06826 | 說明 | H 股 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | 事件 | 已發行股份（不包括 ...

上海昊海生物科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6826） 海外監管公告 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Shanghai Haohai Biological Technology Co., Ltd.* 本公告乃由上海昊海生物科技股份有限公司（「本公司」）根據《香港聯合交易所有 限公司證券上市規則》第13.10B條的規定刊發。 * 僅供識別 证券代码：688366 证券简称：昊海生科 公告编号：2024-057 上海昊海生物科技股份有限公司 股东减持股份计划期限届满未减持股份的结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 茲載列本公司在上海證券交易所網站刊登之《上海昊海生物科技股份有限公司股 東減持股份計劃期限屆滿未減持股份的結果公告》，僅供參考。 承董事會命 上海昊海生物科技股份有限公 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 上海昊海生物科技股份有限公司（於中華人民共和國註冊成立的股份有限公司） 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 | 1). | 於 2024 年8月20日回購股份但尚未註銷 | 102,100 | % | HKD | 28.9 | | --- | --- | --- | --- | --- | --- | | | 變動日期 2024年8月20日 | | | | | | 2). | 於 2024 年8月21日回購股份但尚未註銷 | 52,500 | % | HKD | 29.29 | | | 變動日期 2024年8月21日 | | | | | | 3). | 於 2024 年8月22日回購股份但尚未註銷 | 56,400 | % | HKD | 29.15 | | | 變動日期 2024年8月22日 | | | | ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 上海昊海生物科技股份有限公司（於中華人民共和國註冊成立的股份有限公司） 呈交日期： 2024年10月28日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 06826 | 說明 | H 股 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 ...

Shanghai Haohai Biological Technology Co., Ltd.* 上海昊海生物科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6826） 董事會成員名單與其角色和職能 上海昊海生物科技股份有限公司董事會（「董事會」）成員載列如下： 獨立非執行董事 姜志宏先生 沈紅波先生 蘇治先生 楊玉社先生 趙磊先生 1 執行董事 侯永泰博士 吳劍英先生 陳奕奕女士 唐敏捷先生 非執行董事 游捷女士 黃明先生 M 相關委員會的成員 中國上海 2024年10月25日 2 董事會設立四個委員會。下表提供各董事會成員在這些委員會中擔任的職位。 | | 委員會 | | | | 戰略與 | | --- | --- | --- | --- | --- | --- | | | | | 薪酬與考核 | | 可持續發展 | | 董事 | | 審計委員會 | 委員會 | 提名委員會 | 委員會 | | 侯永泰博士 | | | | M | M | | 吳劍英先生 | | | M | | M | | 陳奕奕女士 | | | | | | | 唐敏捷先生 | | | | | | | 游捷女士 | ...

上海昊海生物科技股份有限公司 （以下簡稱「公司」） 董事會戰略及可持續發展委員會工作細則 （由公司第五屆董事會第二十七次會議於2024年10月25日審議通過） 第一章 總則 第一條 為適應公司戰略發展需要，增強公司核心競爭力，確定公司發展規 劃，健全投資決策程序，加強決策科學性，提高重大投資決策的效益和決策的質 量，完善公司治理結構，公司董事會（以下簡稱「董事會」）根據《中華人民共和國 公司法》、《上海證券交易所科創板股票上市規則》、《香港聯合交易所有限公司證 券上市規則》、《上海昊海生物科技股份有限公司章程》（以下簡稱「《公司章程》」） 及公司股票上市地證券監督管理機構的有關規定，特決定設立董事會戰略及可持 續發展委員會（以下簡稱「委員會」），作為負責協助董事會管理公司長期發展戰 略、重大投資決策、可持續發展以及環境、社會及管治（以下簡稱「ESG」）相關事 宜的專門機構，並制訂本工作細則。 第二條 委員會向董事會提出建議和實施方案，所作決議必須遵守《公司章 程》、本工作細則及其他有關法律、法規和規範性文件的規定。 第三條 委員會根據《公司章程》和本工作細則履行職責，獨立工作，不受公 司其他部門干涉。 第二章 ...

Financial Performance - The company's operating revenue for Q3 2024 was ¥670,367,536.60, representing a year-on-year increase of 0.22%[2] - The net profit attributable to shareholders for the same period was ¥105,605,379.86, a decrease of 13.13% compared to the previous year[2] - The basic earnings per share for Q3 2024 was ¥0.45, down 11.76% from the same period last year[2] - The weighted average return on net assets was 1.85%, a decrease of 0.25 percentage points compared to the previous year[2] - The total operating revenue for the first three quarters of 2024 reached ¥2,074,811,249.42, an increase of 4.4% compared to ¥1,981,789,458.11 in the same period of 2023[17] - The net profit for the first three quarters of 2024 was ¥315,982,692.70, compared to ¥326,967,441.02 in 2023, indicating a decrease of 3.0%[17] - The net profit attributable to the parent company shareholders for the current period is approximately ¥340.89 million, compared to ¥326.80 million in the previous period, representing an increase of about 4.3%[19] - The total comprehensive income attributable to the parent company for the current period is approximately ¥339.62 million, compared to ¥320.28 million in the previous period, showing an increase of about 6%[19] Research and Development - The R&D investment totaled ¥62,736,101.10 in Q3 2024, which is an increase of 18.90% year-on-year, accounting for 9.36% of operating revenue[3] - The company plans to continue increasing its R&D investment to enhance product development and market competitiveness[3] - Research and development expenses for the first three quarters of 2024 were ¥188,136,393.76, up from ¥154,154,668.27 in the same period of 2023, representing a growth of 22.0%[17] Assets and Liabilities - The total assets at the end of the reporting period reached ¥7,245,126,695.06, reflecting a year-on-year increase of 1.97%[3] - The total assets increased to ¥7,245,126,695.06 as of September 30, 2024, compared to ¥7,105,496,951.15 at the end of 2023, marking a growth of 1.96%[15] - The total liabilities rose to ¥1,212,109,544.85 from ¥1,088,203,977.97, reflecting an increase of 11.4%[15] - The total equity attributable to shareholders was ¥5,669,077,729.64, a slight increase of 0.34% from the previous year[3] - The total owner's equity as of September 30, 2024, was ¥6,033,017,150.21, slightly up from ¥6,017,292,973.18 at the end of 2023[15] Cash Flow - The net cash flow from operating activities for the year-to-date was ¥430,639,272.85, an increase of 9.98% year-on-year[3] - The net cash flow generated from operating activities for the first three quarters of 2024 is approximately ¥430.64 million, up from ¥391.56 million in the same period of 2023, indicating a growth of about 10%[21] - The company received approximately ¥65.50 million in cash related to operating activities, an increase from ¥37.36 million in the previous year, representing a growth of about 75.5%[21] - The net cash flow from financing activities for the current period is approximately -¥235.04 million, worsening from -¥157.89 million in the previous period[23] Costs and Expenses - The total operating costs for the same period were ¥1,699,560,309.60, up from ¥1,616,376,970.69, reflecting a year-on-year increase of 5.1%[17] - The company reported a decrease in sales expenses to ¥594,490,949.81 from ¥625,680,738.33, a reduction of 5.0% year-on-year[17] - The company's long-term equity investments increased to ¥3,682,116.04 from ¥3,471,429.56, showing a growth of 6.1%[14] Cash and Equivalents - The company's cash and cash equivalents as of September 30, 2024, were ¥2,625,259,691.85, down from ¥2,740,678,648.51 at the end of 2023[14] - The cash and cash equivalents at the end of the period amount to approximately ¥917.47 million, compared to ¥406.36 million at the end of the previous period, indicating a significant increase of about 126.5%[23] - The total cash inflow from investment activities for the first three quarters of 2024 is approximately ¥1.50 billion, compared to ¥1.09 billion in the previous year, reflecting an increase of about 37.4%[21] - The cash inflow from sales of goods and services for the first three quarters of 2024 is approximately ¥2.19 billion, compared to ¥2.15 billion in the same period of 2023, reflecting a growth of about 1.5%[21] Minority Interests - The company reported a decrease in minority shareholders' profit, with a loss of approximately -¥24.91 million compared to a profit of ¥0.16 million in the previous period[19]

上海昊海生物科技股份有限公司 （以下簡稱「公司」） 董事會審計委員會工作細則 （由公司第五屆董事會第二十七次會議於2024年10月25日審議通過） 第一章 總則 第一條 為強化董事會決策功能，實現對公司財務收支和各項經營活動的有 效監督，做到事前審計、專業審計，確保董事會對經理層的有效監督，進一步完 善公司治理結構，公司董事會（以下簡稱「董事會」）根據《中華人民共和國公司 法》（以下簡稱「《公司法》」）、《上海證券交易所科創板股票上市規則》（以下簡稱 「科創板上市規則」）、《香港聯合交易所有限公司證券上市規則》（以下簡稱「香港 上市規則」）、《上海昊海生物科技股份有限公司章程》（以下簡稱「《公司章程》」）及 其它有關規定，特決定設立董事會審計委員會（以下簡稱「委員會」），並制訂本工 作細則。 第二條 委員會所作決議，必須遵守《公司章程》、本工作細則及其他有關法 律、法規和規範性文件的規定。 第三條 委員會根據《公司章程》和本工作細則履行職責，獨立工作，不受公 司其他部門干涉。 第二章 人員構成 第四條 委員會由不少於3名董事組成，委員全部是非執行董事，獨立非執行 董事應在委員會委員中佔大多數。委員中至少有1名 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Shanghai Haohai Biological Technology Co., Ltd.* 上海昊海生物科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6826） 2024年第三季度報告； 戰略委員會及審計委員會工作細則修訂；及 戰略委員會更名 2024年第三季度報告 本部分公告乃上海昊海生物科技股份有限公司（「本公司」，連同其附屬公司統稱 「本集團」）根據香港聯合交易所有限公司證券上市規則第13.09(2)及13.10B條以及 香港法例第571章證券及期貨條例第XIVA部刊發，旨在向本公司股東及公眾人士 提供本公司最新的財務資料。 茲載列本公司同時在上海證券交易所網站發佈的、截至2024年9月30日止三個月 及九個月之本集團未經審計業績（「第三季度報告」）。第三季度報告所載財務數據 乃根據中國企業會計準則編製，且未經審計。以下所載第三季度報告以中英文版 本編製。有任何歧 ...

Financial Performance - For the six months ended June 30, 2024, the company recorded revenue of approximately RMB 1,397.11 million, an increase of approximately RMB 91.40 million or 7.00% compared to RMB 1,305.71 million in the same period of 2023[9]. - Profit attributable to ordinary equity holders was approximately RMB 235.28 million, an increase of approximately RMB 30.04 million or 14.64% from RMB 205.24 million in the same period of 2023[9]. - Basic earnings per share for the period were RMB 1.01, compared to RMB 0.86 in the same period of 2023[9]. - The group reported a revenue of approximately RMB 1,397.11 million for the reporting period, an increase of RMB 91.40 million or 7.00% compared to RMB 1,305.71 million in the same period of 2023[38]. - Total comprehensive income for the six months ended June 30, 2024, was RMB 196,737,000, a decrease of 21.2% from RMB 249,563,000 in the same period of 2023[57]. - The profit attributable to equity holders of the parent company increased to RMB 235,283,000, up 14.6% from RMB 205,235,000 year-on-year[57]. - The group’s profit before tax for the six months ended June 30, 2024, was RMB 235,283,000, compared to RMB 205,235,000 for the same period in 2023, representing an increase of approximately 14.6%[84]. Revenue Breakdown - Revenue from the medical beauty and wound care product line was RMB 631.82 million, accounting for 45.22% of total revenue, with a year-on-year growth of 25.53%[11]. - Revenue from ophthalmic products was RMB 449.66 million, accounting for 32.18% of total revenue, showing a decline of 6.15% year-on-year[11]. - Revenue from orthopedic products was RMB 231.82 million, accounting for 16.59% of total revenue, with a slight increase of 0.28% year-on-year[11]. - Revenue from anti-adhesion and hemostatic products was RMB 68.87 million, accounting for 4.93% of total revenue, with a decline of 2.55% year-on-year[11]. - Revenue from the mainland China market was RMB 1,179,576 thousand, an increase of 11.3% from RMB 1,059,733 thousand in the previous year[71]. Research and Development - Research and development expenses for the period were approximately RMB 125.40 million, up by approximately RMB 24.01 million or 23.68% year-on-year, representing 8.98% of total revenue compared to 7.77% in 2023[9]. - The clinical trials for several key R&D projects progressed smoothly during the reporting period, including new high-oxygen contact lens products[12]. - The company continues to focus on the production and sales of bioproducts, medical-grade hyaluronic acid, and artificial lenses, with ongoing R&D in biotechnology and pharmaceuticals[70]. - Research and development costs increased to RMB 125,400,000 for the six months ended June 30, 2024, from RMB 101,391,000 in the same period of 2023, reflecting a growth of about 23.7%[78]. Dividends and Shareholder Returns - The board proposed an interim dividend of RMB 0.40 per share (tax included) for the six months ended June 30, 2024, compared to no dividend in the same period of 2023[9]. - The company proposed an interim dividend of RMB 0.40 per ordinary share, totaling RMB 93,192,000, compared to no dividend for the same period in 2023[82]. Market Position and Growth - The market share of the epidermal growth factor product "Kanghesu" was 26.91% in 2023, maintaining the second position in the domestic market[13]. - The company plans to expand the application of its epidermal growth factor product to multiple departments beyond traditional uses, enhancing its market reach[18]. - The Chinese medical aesthetics market is expected to grow by approximately 10% in 2024, with a compound annual growth rate of 10-15% over the next four years[17]. - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by the end of 2025[154]. Cash Flow and Financial Position - Operating cash flow for the six months ended June 30, 2024, was RMB 380,712,000, an increase of 17.1% from RMB 325,038,000 in the same period of 2023[64]. - Cash and cash equivalents as of June 30, 2024, were approximately RMB 924.21 million, an increase of RMB 354.89 million from approximately RMB 569.32 million as of December 31, 2023[51]. - Total current assets as of June 30, 2024, were approximately RMB 3,720.36 million, a decrease of RMB 29.78 million or 0.79% from December 31, 2023[44]. - Total liabilities as of June 30, 2024, were approximately RMB 1,186.37 million, with a debt-to-asset ratio of 16.38%, an increase of 1.07 percentage points from 15.31% as of December 31, 2023[50]. Acquisitions and Investments - The company acquired 51% of Shanghai Shenhao Mijian Technology Development Co., Ltd. for a total consideration of RMB 36.2885 million, completed in June 2024[28]. - The cash outflow from investing activities related to the acquisition of Shenhao Mijian was RMB 16,009,000 after accounting for cash acquired[106]. Corporate Governance and Compliance - The interim financial report was approved by the board on August 16, 2024, and published on the Hong Kong Stock Exchange website[123]. - The company has complied with all applicable code provisions under the Corporate Governance Code during the reporting period[146]. - There were no significant legal proceedings or arbitrations involving the company during the reporting period[150]. Employee Compensation and Incentives - Employee compensation for the reporting period totaled approximately RMB 337.30 million, an increase of RMB 21.77 million from approximately RMB 315.53 million in the same period of 2023[46]. - The company has granted a total of 1,800,000 restricted shares under the 2021 A-share incentive plan, with the first vesting period completed[137]. - Total remuneration for key management personnel amounted to RMB 4,447,000 for the six months ended June 30, 2024, compared to RMB 3,471,000 for the same period in 2023, representing an increase of 28.1%[111].